Highlights:

  • Authorization from the Brazilian Health Regulatory Agency (ANVISA) allows for Khiron medical cannabis product to be imported for use on an individual patient basis
  • Authorization follows December 2019 announcement by ANVISA allowing for a new class of medical cannabis-based product to be prescribed by doctors and sold through pharmacies, enabling patient safe and legal access
  • In Colombia, Company prepares for final authorization milestone allowing for domestic medical cannabis distribution
  • Brazil represents the largest addressable market in Latin America with an anticipated 3.4 million patient population and a potential USD $1.4 Billion network for medical cannabis (New Frontier Data)

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV:KHRN, OTCQB:KHRNF, Frankfurt:A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that the Brazilian Health Regulatory Agency (ANVISA) has authorized for Khiron medical cannabis product to be imported into Brazil on an individual patient basis. This authorization will enable the Company to apply for a permit to export the product from Colombia. Commercialization in Brazil is also conditional on TSXV approval.


“Within our LatAm strategy receipt of this authorization from ANVISA represents another regulatory milestone in bringing our medical cannabis products to the largest patient market in Latin America. With a continued focus on the health and wellbeing of patients in the region, we continue to grow our network in Brazil as we also work towards pending authorizations in Colombia and Peru.” Comments Alvaro Torres, Khiron CEO and Director.

The announced regulatory framework, administered by the Brazilian Health Regulatory Agency (ANVISA), sets a comprehensive procedure for the manufacture and import of medical cannabis products and requirements for commercialization, prescription and dispensing. In the announcement, a new class of medical cannabis-based products will be prescribed by doctors and sold through pharmacies, enabling patient safe and legal access.

The medical cannabis market in Brazil is anticipated to grow to 3.4 million patients and a market of US$1.4 Billion within three years, including serving patients with chronic pain conditions (Source: New Frontier Data). Further, total requests for medical cannabis have tripled since 2015 (Source: ANVISA) and today, approximately 1,100 physicians are now prescribing medical cannabis to their patients.

About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.

Visit Khiron online at www.khiron.ca and on Instagram @khironlife

Cautionary Notes

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN, OTC:KHRNF) for an Investor Presentation.

Source

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

A Toronto-based company is set to become the first cannabis operation to transition to the real estate investment trust (REIT) model.

At the start of October, Subversive Real Estate Acquisition REIT LP (NEO:SVX.U,OTC Pink:SBVRF) announced to the market a qualifying transaction that will allow it to finish the process of becoming a special purpose acquisition company (SPAC).

Keep reading... Show less

CEO recognized for economic development across the minority community in the Big Bend Florida region

Trulieve Cannabis Corp. (CSE: TRUL & OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that Chief Executive Officer Kim Rivers was awarded the 2020 Women Business Enterprise of the Year Award. The award celebrates the work of businesses and leaders in Florida’s Big Bend area who are driving innovation, expanding a business, and fostering job creation in the majority-minority community.

Keep reading... Show less

The 64 th storefront in Florida offers the largest inventory of medical cannabis products in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 66th nationwide. The new dispensary will be the first location in Punta Gorda and third in Charlotte County to bring the Company’s wide-ranging catalog of medical cannabis products directly to patients.

Keep reading... Show less
  • Existing At-The-Market (ATM) program now complete
  • New Preliminary Base Shelf Prospectus Has Been Filed
  • Current Cash Position is Approximately $272 million

NYSE | TSX: ACB

Aurora Cannabis Inc. (the ” Company ” or ” Aurora “) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced it has completed the previously filed At-The-Market (“ATM”) program. Because of this, the Company has filed a new preliminary short form base shelf prospectus (the “Shelf Prospectus”) with securities regulators in each of the provinces of Canada except Quebec and a corresponding shelf registration statement on Form F–10 (the “Registration Statement”) with the United States Securities and Exchange Commission (the “SEC”).

Keep reading... Show less

 Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has completed an initial production run of all four of its Ayurvedic, functional mushroom coffees.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/66901_b3bb261db486a838_001.jpg

Keep reading... Show less